Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1086/508280 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!